# Michelle A Lowes

List of Publications by Year
in descending order



| 104 | 13,866 | 34105 52 | 29157 104 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 110 | 110 | 110 | 12100 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Pathogenesis and therapy of psoriasis. Nature, 2007, 445, 866-873. | 27.8 | 1,543 |
| 2 | Immunology of Psoriasis. Annual Review of Immunology, 2014, 32, 227-255. | 21.8 | 1,242 |
| 3 | Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells. Journal of Investigative Dermatology, 2008, 128, 1207-1211. | 0.7 | 910 |
| 4 | Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. British Journal of Dermatology, 2008, 159, ???-???. | 1.5 | 666 |
| 5 | Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. Journal of Experimental Medicine, 2007, 204, 3183-3194. | 8.5 | 604 |
| 6 | Increase in TNF-Î± and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 19057-19062. | 7.1 | 426 |
| 7 | The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends in Immunology, 2013, 34, 174-181. | 6.8 | 399 |
| 8 | Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic Cells. Journal of Investigative Dermatology, 2009, 129, 79-88. | 0.7 | 374 |
| 9 | PSORS2 Is Due to Mutations in CARD14. American Journal of Human Genetics, 2012, 90, 784-795. | 6.2 | 365 |
| 10 | TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques. Journal of Immunology, 2005, 175, 2721-2729. | 0.8 | 348 |
| 11 | Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in Psoriasis. American Journal of Human Genetics, 2012, 90, 796-808. | 6.2 | 306 |
| 12 | Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis. Journal of Immunology, 2008, 181, 7420-7427. | 0.8 | 300 |
| 13 | Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. Journal of Allergy and Clinical Immunology, 2009, 124, 1022-1030.e395. | 2.9 | 273 |
| 14 | Resident and â€œInflammatoryâ€•Dendritic Cells in Human Skin. Journal of Investigative Dermatology, 2009, 129, 302-308. | 0.7 | 262 |
| 15 | Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. Journal of Clinical Investigation, 2007, 117, 2517-2525. | 8.2 | 262 |
| 16 | A Subpopulation of CD163-Positive Macrophages Is Classically Activated in Psoriasis. Journal of Investigative Dermatology, 2010, 130, 2412-2422. | 0.7 | 249 |
| 17 | Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. Journal of Allergy and Clinical Immunology, 2007, 119, 1210-1217. | 2.9 | 220 |
| 18 | North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 76-90. | 1.2 | 218 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | North American clinical management guidelines for hidradenitis suppurativa: AÂpublication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 91-101. | 1.2 | 206 |
| 20 | Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2075-2080. | 7.1 | 203 |
| 21 | Identification of Cellular Pathways of â€œType 1,â€•Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis. Journal of Immunology, 2008, 180, 1913-1920. | 0.8 | 165 |
| 22 | Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of the American Academy of Dermatology, 2020, 82, 366-376. | 1.2 | 165 |
| 23 | Resolved Psoriasis Lesions Retain Expression of a Subset of Disease-Related Genes. Journal of Investigative Dermatology, 2011, 131, 391-400. | 0.7 | 164 |
| 24 | Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA). PLoS ONE, 2010, 5, e10247. | 2.5 | 161 |
| 25 | Tumor-Associated Macrophages in the Cutaneous SCC Microenvironment Are Heterogeneously Activated. Journal of Investigative Dermatology, 2011, 131, 1322-1330. | 0.7 | 160 |
| 26 | IL-17 and TNF Synergistically Modulate Cytokine Expression while Suppressing Melanogenesis: Potential Relevance to Psoriasis. Journal of Investigative Dermatology, 2013, 133, 2741-2752. | 0.7 | 156 |
| 27 | Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the â€œCoreâ€•Pathogenesis of Disease. PLoS ONE, 2012, 7, e44274. | 2.5 | 149 |
| 28 | IFNÎ³-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. Cell, 2017, 170, 127-141.e15. | 28.9 | 140 |
| 29 | Effective Narrow-Band UVB Radiation Therapy Suppresses the IL-23/IL-17 Axis in Normalized Psoriasis Plaques. Journal of Investigative Dermatology, 2010, 130, 2654-2663. | 0.7 | 136 |
| 30 | Putting together the psoriasis puzzle: an update on developing targeted therapies. DMM Disease Models and Mechanisms, 2012, 5, 423-433. | 2.4 | 111 |
| 31 | Human Basal Cell Carcinoma Is Associated with Foxp3+ T cells in a Th2 Dominant Microenvironment. Journal of Investigative Dermatology, 2007, 127, 2391-2398. | 0.7 | 109 |
| 32 | The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. Journal of Allergy and Clinical Immunology, 2016, 137, 1830-1840. | 2.9 | 108 |
| 33 | T Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas. Journal of Investigative Dermatology, 1997, 108, 914-919. | 0.7 | 104 |
| 34 | Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. Journal of Allergy and Clinical Immunology, 2010, 125, 1261-1268.e9. | 2.9 | 95 |
| 35 | A Single Intradermal Injection of IFN-Î³ Induces an Inflammatory State in Both Non-Lesional Psoriatic and Healthy Skin. Journal of Investigative Dermatology, 2012, 132, 1177-1187. | 0.7 | 94 |
| 36 | Humanized antiâ€“IFN-Î³ (HuZAF) in the treatment of psoriasis. Journal of Allergy and Clinical Immunology, 2015, 135, 553-556.e3. | 2.9 | 93 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Pathophysiology of hidradenitis suppurativa. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 47-54. | 1.6 | 93 |
| 38 | Cytokine-Producing Dendritic Cells in the Pathogenesis of Inflammatory Skin Diseases. Journal of Clinical Immunology, 2009, 29, 247-256. | 3.8 | 90 |
| 39 | What causes hidradenitis suppurativa ?â€”15 years after. Experimental Dermatology, 2020, 29, 1154-1170. | 2.9 | 90 |
| 40 | Prominent Production of IL-20 by CD68+/CD11c+ Myeloid-Derived Cells in Psoriasis: Gene Regulation and Cellular Effects. Journal of Investigative Dermatology, 2006, 126, 1590-1599. | 0.7 | 88 |
| 41 | Transient reactive papulotranslucent acrokeratoderma associated with cystic fibrosis. Australasian Journal of Dermatology, 2000, 41, 172-174. | 0.7 | 87 |
| 42 | Cytokine profiles in spontaneously regressing basal cell carcinomas. British Journal of Dermatology, 2000, 143, 91-98. | 1.5 | 84 |
| 43 | Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. Journal of Investigative Dermatology, 2011, 131, 1322-30. | 0.7 | 81 |
| 44 | Myeloid Dendritic Cells from Human Cutaneous Squamous Cell Carcinoma Are Poor Stimulators of T-Cell Proliferation. Journal of Investigative Dermatology, 2009, 129, 2451-2462. | 0.7 | 79 |
| 45 | Pain, Psychological Comorbidities, Disability, and Impaired Qualify of Life in Hidradenitis Suppurativa. Current Pain and Headache Reports, 2017, 21, 49. | 2.9 | 77 |
| 46 | Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2022, 86, 1092-1101. | 1.2 | 77 |
| 47 | Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clinical Immunology, 2004, 113, 38-46. | 3.2 | 74 |
| 48 | Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. PLoS ONE, 2018, 13, e0203672. | 2.5 | 71 |
| 49 | A Comparison of International Management Guidelines for Hidradenitis Suppurativa. Dermatology, 2021, 237, 81-96. | 2.1 | 68 |
| 50 | Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. Journal of Translational Medicine, 2007, 5, 27. | 4.4 | 60 |
| 51 | Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease. Skin Pharmacology and Physiology, 2018, 31, 246-251. | 2.5 | 56 |
| 52 | Novel Insight into the Agonistic Mechanism of Alefacept In Vivo: Differentially Expressed Genes May Serve as Biomarkers of Response in Psoriasis Patients. Journal of Immunology, 2007, 178, 7442-7449. | 0.8 | 54 |
| 53 | Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness. Journal of Investigative Dermatology, 2008, 128, 1182-1191. | 0.7 | 54 |
| 54 | Quality of life and sexual health in patients with hidradenitis suppurativa. International Journal of Women's Dermatology, 2018, 4, 74-79. | 2.0 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | CARD14 Expression in Dermal Endothelial Cells in Psoriasis. PLoS ONE, 2014, 9, e111255. | 2.5 | 52 |
| 56 | Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. Journal of Investigative Dermatology, 2016, 136, 161-172. | 0.7 | 51 |
| 57 | The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, butÂwith Key Differences in Immune Regulatory Genes. Journal of Investigative Dermatology, 2016, 136, 2173-2182. | 0.7 | 47 |
| 58 | TREM-1 as a Potential Therapeutic Target in Psoriasis. Journal of Investigative Dermatology, 2013, 133, 1742-1751. | 0.7 | 46 |
| 59 | Gene Profiling of Narrowband UVBâ€“Induced Skin Injury Defines Cellular and Molecular Innate Immune Responses. Journal of Investigative Dermatology, 2013, 133, 692-701. | 0.7 | 44 |
| 60 | A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance. Journal of Investigative Dermatology, 2021, 141, 316-324.e2. | 0.7 | 44 |
| 61 | Current concepts in the immunopathogenesis of psoriasis. Dermatologic Clinics, 2004, 22, 349-369. | 1.7 | 42 |
| 62 | Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept. BMC Dermatology, 2010, 10, 1. | 2.1 | 42 |
| 63 | Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment. Journal of Investigative Dermatology, 2018, 138, 273-281. | 0.7 | 40 |
| 64 | Distribution of Self-reported Hidradenitis Suppurativa Age at Onset. JAMA Dermatology, 2019, 155, 971. | 4.1 | 40 |
| 65 | Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis. F1000Research, 2015, 4, 460. | 1.6 | 40 |
| 66 | Pain management in hidradenitis suppurativa and a proposed treatment algorithm. Journal of the American Academy of Dermatology, 2021, 85, 187-199. | 1.2 | 37 |
| 67 | Homeostatic Tissue Responses in Skin Biopsies from NOMID Patients with Constitutive Overproduction of IL-1Î². PLoS ONE, 2012, 7, e49408. | 2.5 | 36 |
| 68 | Benign melanocytic proliferative nodule within a congenital naevus. Australasian Journal of Dermatology, 2000, 41, 109-111. | 0.7 | 33 |
| 69 | Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa. JAMA Dermatology, 2022, 158, 300. | 4.1 | 33 |
| 70 | Cellular Genomic Maps Help Dissect Pathology in Human Skin Disease. Journal of Investigative Dermatology, 2008, 128, 606-615. | 0.7 | 31 |
| 71 | Post-Therapeutic Relapse of Psoriasis after CD11a Blockade Is Associated with T Cells and Inflammatory Myeloid DCs. PLoS ONE, 2012, 7, e30308. | 2.5 | 29 |
| 72 | Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. British Journal of Dermatology, 2019, 181, 1339-1341. | 1.5 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2020, 140, 531-536.e1. | 0.7 | 28 |
| 74 | A randomized clinical trial in vitamin Dâ€“deficient adults comparing replenishment with oral vitamin D3 with narrow-band UV type B light: effects on cholesterol and the transcriptional profiles of skin and blood ,. American Journal of Clinical Nutrition, 2017, 105, 1230-1238. | 4.7 | 27 |
| 75 | Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatology, 2005, 5, 9. | 2.1 | 26 |
| 76 | Are Bacteria Infectious Pathogens in Hidradenitis Suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017. Journal of Investigative Dermatology, 2019, 139, 13-16. | 0.7 | 26 |
| 77 | Major gaps in understanding and treatment of hidradenitis suppurativa. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 86-92. | 1.6 | 22 |
| 78 | Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. BMC Dermatology, 2007, 7, 2. | 2.1 | 20 |
| 79 | African American Patients With Hidradenitis Suppurativa Have Significant Health Care Disparities: A Retrospective Study. Journal of Cutaneous Medicine and Surgery, 2019, 23, 334-336. | 1.2 | 18 |
| 80 | Special considerations for women with hidradenitis suppurativa. International Journal of Women's Dermatology, 2020, 6, 85-88. | 2.0 | 17 |
| 81 | Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. British Journal of Dermatology, 2021, 184, 1004-1013. | 1.5 | 15 |
| 82 | Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review. Journal of the American Academy of Dermatology, 2020, 82, 45-53. | 1.2 | 13 |
| 83 | Polyclonal hyperglobulinaemia and elevated acute-phase reactants in hidradenitis suppurativa. British Journal of Dermatology, 2018, 178, e134-e135. | 1.5 | 11 |
| 84 | Diagnosis and management of hidradenitis suppurativa in women. American Journal of Obstetrics and Gynecology, 2021, 224, 54-61. | 1.3 | 10 |
| 85 | Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series. American Journal of Clinical Dermatology, 2021, 22, 275-283. | 6.7 | 8 |
| 86 | Hemoglobin Levels and Serum C-Reactive Protein in Patients With Moderate to Severe Hidradenitis Suppurativa. Journal of Cutaneous Medicine and Surgery, 2019, 23, 501-506. | 1.2 | 7 |
| 87 | Expert Knowledge, Attitudes, and Practices in Management of Hidradenitis Suppurativa Pain. JAMA Dermatology, 2021, 157, 464. | 4.1 | 7 |
| 88 | Clinical considerations in the management of hidradenitis suppurativa in women. International Journal of Women's Dermatology, 2021, 7, 664-671. | 2.0 | 7 |
| 89 | Lack of Functionally Active Melan-A26â€“35-Specific T Cells in the Blood of HLA-A2+ Vitiligo Patients. Journal of Investigative Dermatology, 2008, 128, 1977-1980. | 0.7 | 6 |
| 90 | Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-Î± Inhibitors?. American Journal of Clinical Dermatology, 2021, 22, 139-147. | 6.7 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Isotretinoin treatment in a patient with known peanut allergy and positive IgE test results for soybean. Annals of Allergy, Asthma and Immunology, 2016, 117, 558-559. | 1.0 | 5 |
| 92 | Hemoglobin as an indicator of disease activity in severe hidradenitis suppurativa. International Journal of Dermatology, 2019, 58, 1090-1091. | 1.0 | 3 |
| 93 | Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa. Dermatologic Therapy, 2021, 34, e14851. | 1.7 | 3 |
| 94 | Provider perspectives on the management of hidradenitis suppurativa in pregnancy â€“ A survey study. International Journal of Women's Dermatology, 2021, 7, 346-348. | 2.0 | 3 |
| 95 | Hidradenitis Suppurativa Specialty Clinics in the USA. Skin Appendage Disorders, 2021, 7, 359-362. | 1.0 | 2 |
| 96 | Patients With Psoriasis and Personalized Trade-offs in Treatment Decisionsâ€”Lessons Learned From Focus Groups. JAMA Dermatology, 2016, 152, 720. | 4.1 | 1 |
| 97 | Creation of a Registry to Address Knowledge Gaps in Hidradenitis Suppurativa and Pregnancyâ€”Reply. JAMA Dermatology, 2020, 156, 354. | 4.1 | 1 |
| 98 | Elevated Plasma Complement Proteins in Palmoplantar Pustulosis: A Potential Therapeutic Target. Journal of Cutaneous Medicine and Surgery, 2021, 25, 449-450. | 1.2 | 1 |
| 99 | Wound Healing in Hidradenitis Suppurativa. Updates in Clinical Dermatology, 2020, , 177-186. | 0.1 | 1 |
| 100 | Diagnosing and Managing Hidradenitis Suppurativa in Pediatrics. Pediatric Annals, 2022, 51, e123-e127. | 0.8 | 1 |
| 101 | CARD14-Mediated Psoriasis and Pityriasis Rubra Piliaris (PRP). , 2018, , 1-4. | | 0 |
| 102 | CARD14-Mediated Psoriasis and Pityriasis Rubra Piliaris (PRP). , 2020, , 92-95. | | 0 |
| 103 | Pipeline Therapeutics. , 2022, , 321-331. | | 0 |
| 104 | Combining medical and surgical management strategies for hidradenitis suppurativa: Need for a treat to target approach. Dermatological Reviews, 2022, 3, 123-125. | 0.5 | 0 |